119 related articles for article (PubMed ID: 22554863)
41. Establishing the pharmaceutical quality of Chinese herbal medicine: a provisional BCS classification.
Fong SY; Liu M; Wei H; Löbenberg R; Kanfer I; Lee VH; Amidon GL; Zuo Z
Mol Pharm; 2013 May; 10(5):1623-43. PubMed ID: 23473440
[TBL] [Abstract][Full Text] [Related]
42. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.
Hilgendorf C; Spahn-Langguth H; Regårdh CG; Lipka E; Amidon GL; Langguth P
J Pharm Sci; 2000 Jan; 89(1):63-75. PubMed ID: 10664539
[TBL] [Abstract][Full Text] [Related]
43. Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs.
Gandhi SV; Rodriguez W; Khan M; Polli JE
AAPS PharmSciTech; 2014 Jun; 15(3):601-11. PubMed ID: 24557773
[TBL] [Abstract][Full Text] [Related]
44. A non-binary biopharmaceutical classification of drugs: the ABΓ system.
Macheras P; Karalis V
Int J Pharm; 2014 Apr; 464(1-2):85-90. PubMed ID: 24456673
[TBL] [Abstract][Full Text] [Related]
45. Mathematical modelling of the transport of hydroxypropyl-β-cyclodextrin inclusion complexes of ranitidine hydrochloride and furosemide loaded chitosan nanoparticles across a Caco-2 cell monolayer.
Sadighi A; Ostad SN; Rezayat SM; Foroutan M; Faramarzi MA; Dorkoosh FA
Int J Pharm; 2012 Jan; 422(1-2):479-88. PubMed ID: 22101294
[TBL] [Abstract][Full Text] [Related]
46. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
[TBL] [Abstract][Full Text] [Related]
47. Classification of loratadine based on the biopharmaceutics drug classification concept and possible in vitro-in vivo correlation.
Khan MZ; Rausl D; Zanoski R; Zidar S; Mikulcić JH; Krizmanić L; Eskinja M; Mildner B; Knezević Z
Biol Pharm Bull; 2004 Oct; 27(10):1630-5. PubMed ID: 15467209
[TBL] [Abstract][Full Text] [Related]
48. Biopharmaceutical characterization of sotalol-containing oral immediate release drug products.
Alt A; Potthast H; Moessinger J; Sickmüller B; Oeser H
Eur J Pharm Biopharm; 2004 Jul; 58(1):145-50. PubMed ID: 15207548
[TBL] [Abstract][Full Text] [Related]
49. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).
Fagerholm U
J Pharm Pharmacol; 2007 Jun; 59(6):751-7. PubMed ID: 17637167
[TBL] [Abstract][Full Text] [Related]
50. A modified physiological BCS for prediction of intestinal absorption in drug discovery.
Zaki NM; Artursson P; Bergström CA
Mol Pharm; 2010 Oct; 7(5):1478-87. PubMed ID: 20734997
[TBL] [Abstract][Full Text] [Related]
51. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
52. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
[TBL] [Abstract][Full Text] [Related]
53. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol.
Vogelpoel H; Welink J; Amidon GL; Junginger HE; Midha KK; Möller H; Olling M; Shah VP; Barends DM
J Pharm Sci; 2004 Aug; 93(8):1945-56. PubMed ID: 15236445
[TBL] [Abstract][Full Text] [Related]
54. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
Lennernäs H; Abrahamsson B
J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
[TBL] [Abstract][Full Text] [Related]
55. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Tsume Y; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
[TBL] [Abstract][Full Text] [Related]
56. Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity.
Tannergren C; Langguth P; Hoffmann KJ
Pharmazie; 2001 Apr; 56(4):337-42. PubMed ID: 11338677
[TBL] [Abstract][Full Text] [Related]
57. The use of drug metabolism for prediction of intestinal permeability (dagger).
Chen ML; Yu L
Mol Pharm; 2009; 6(1):74-81. PubMed ID: 19132929
[TBL] [Abstract][Full Text] [Related]
58. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers.
Ingels F; Beck B; Oth M; Augustijns P
Int J Pharm; 2004 Apr; 274(1-2):221-32. PubMed ID: 15072798
[TBL] [Abstract][Full Text] [Related]
59. Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using in silico modeling.
Crison JR; Timmins P; Keung A; Upreti VV; Boulton DW; Scheer BJ
J Pharm Sci; 2012 May; 101(5):1773-82. PubMed ID: 22334460
[TBL] [Abstract][Full Text] [Related]
60. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.
Tannergren C; Bergendal A; Lennernäs H; Abrahamsson B
Mol Pharm; 2009; 6(1):60-73. PubMed ID: 19183105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
